Quartz Partners LLC Purchases 831 Shares of Cencora, Inc. (NYSE:COR)

Quartz Partners LLC lifted its holdings in Cencora, Inc. (NYSE:COR) by 10.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,853 shares of the company’s stock after acquiring an additional 831 shares during the quarter. Cencora makes up approximately 1.2% of Quartz Partners LLC’s holdings, making the stock its 19th largest holding. Quartz Partners LLC’s holdings in Cencora were worth $1,989,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Swedbank AB lifted its position in Cencora by 2.3% during the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after purchasing an additional 31,104 shares during the period. Allworth Financial LP raised its stake in shares of Cencora by 22.8% during the third quarter. Allworth Financial LP now owns 1,672 shares of the company’s stock worth $376,000 after buying an additional 310 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Cencora by 4.3% during the third quarter. Louisiana State Employees Retirement System now owns 9,800 shares of the company’s stock worth $2,206,000 after buying an additional 400 shares during the last quarter. Parcion Private Wealth LLC lifted its holdings in Cencora by 90.9% in the third quarter. Parcion Private Wealth LLC now owns 1,791 shares of the company’s stock valued at $403,000 after buying an additional 853 shares during the period. Finally, Forsta AP Fonden boosted its stake in Cencora by 9.0% in the third quarter. Forsta AP Fonden now owns 69,270 shares of the company’s stock valued at $15,591,000 after acquiring an additional 5,700 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Down 0.8 %

Shares of COR stock opened at $241.47 on Monday. The company has a market capitalization of $46.83 billion, a price-to-earnings ratio of 34.35, a P/E/G ratio of 1.31 and a beta of 0.49. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The firm has a fifty day moving average of $239.52 and a 200-day moving average of $237.42. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Friday, February 14th. Cencora’s payout ratio is 31.29%.

Analysts Set New Price Targets

Several analysts have commented on the stock. Robert W. Baird upped their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Wells Fargo & Company upped their price objective on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. increased their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Mizuho assumed coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target on the stock. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.